On August 1, 2021, the board of directors (the “Board”) of CM Life Sciences III Inc. (the “Company”) determined to increase the size of the Board from six directors to seven directors, and appointed Dr. Amy Abernethy, M.D., Ph.D. to the newly created directorship, effective August 2, 2021. Dr. Abernethy will serve as a Class II director until the Company’s second annual meeting of stockholders and until her successor is duly elected and qualified. Dr. Abernethy is the President of the Clinical Research Business of Verily Life Sciences Inc. Before joining Verily in July, Dr. Abernethy was Principal Deputy Commissioner and Acting Chief Information Officer of the U.S. Food & Drug Administration (the “FDA”) from February 2019 to April 2021.